Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Pfizer “Share Card” Playing Well: 185,000 Seniors Enrolled

  • News

Executive Summary

The Pfizer "Share Card" senior drug discount program is generating over $1 mil. a month in revenue

You may also be interested in...



“Together Rx” Card Unites 7 Firms; Merck, Pharmacia, Wyeth Stay Apart

The "Together Rx" drug discount program could serve as the basis of a unified manufacturer/pharmacy program, McKesson Supply Solutions President Paul Julian told an April 10 press conference in New York City

NACDS Interim Medicare Rx Plan: “OneCard” Plus Stop-Loss Coverage

The National Association of Chain Drug Stores is pushing its "OneCard" program as part of a two-prong interim legislative solution to help seniors afford prescription drugs in the absence of a Medicare Rx benefit

Pfizer “Share Card” Follows Flat Fee Policy; Seniors Pay $15 Per Rx

Pfizer's "Share Card" senior prescription card program offers seniors a flat $15 price per prescription for Pfizer products in lieu of the discount model used by other card plans

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS040275

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By